The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 09, 2024
Filed:
Jan. 27, 2017
Applicant:
Epizyme, Inc., Cambridge, MA (US);
Inventor:
Maria Alejandra Raimondi, Jamaica Plain, MA (US);
Assignee:
EPIZYME, INC., Cambridge, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/5377 (2006.01); A61K 31/138 (2006.01); A61K 31/166 (2006.01); A61K 31/167 (2006.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 31/4045 (2006.01); A61K 31/4196 (2006.01); A61K 31/436 (2006.01); A61K 31/437 (2006.01); A61K 31/4375 (2006.01); A61K 31/4406 (2006.01); A61K 31/4439 (2006.01); A61K 31/4545 (2006.01); A61K 31/4745 (2006.01); A61K 31/502 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/52 (2006.01); A61K 31/551 (2006.01); A61K 31/555 (2006.01); A61K 31/567 (2006.01); A61K 31/575 (2006.01); A61K 31/635 (2006.01); A61K 31/675 (2006.01); A61K 31/704 (2006.01); A61K 31/7048 (2006.01); A61K 31/706 (2006.01); A61K 31/7068 (2006.01); A61K 33/243 (2019.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5377 (2013.01); A61K 31/138 (2013.01); A61K 31/166 (2013.01); A61K 31/167 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/4045 (2013.01); A61K 31/4196 (2013.01); A61K 31/436 (2013.01); A61K 31/437 (2013.01); A61K 31/4375 (2013.01); A61K 31/4406 (2013.01); A61K 31/4439 (2013.01); A61K 31/4545 (2013.01); A61K 31/4745 (2013.01); A61K 31/502 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/52 (2013.01); A61K 31/551 (2013.01); A61K 31/555 (2013.01); A61K 31/567 (2013.01); A61K 31/575 (2013.01); A61K 31/635 (2013.01); A61K 31/675 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 31/706 (2013.01); A61K 31/7068 (2013.01); A61K 33/243 (2019.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01);
Abstract
The disclosure relates to a method for treatment of cancer comprising administering to a subject in need thereof a first agent in a therapeutically effective amount and a second agent in a therapeutically effective amount. Preferably, the first agent comprises an EZH2 inhibitor, e.g., tazemetostat or a pharmaceutically acceptable salt thereof. In certain embodiments, the methods of the disclosure are used to treat breast cancer, ovarian cancer, or both.